Kornimate/medical-research-clean huggingface dataset:
effects of extracorporeal shock wave therapy and low level laser therapy in myofascial pain syndrome

Conditions: Myofascial Pain Syndrome

Summary: this study evaluates the effects of low level laser therapy and extracorporeal shock wave therapy in patients with myofascial pain syndrome of the upper trapezius. half of the patients receive laser therapy, half of them receive shock wave therapy for three weeks.

low level laser therapy (lllt) inducing photochemical and photothermal effect, increases blood flow and vascular permeability and improves cell metabolism. all these lead to muscle recovery. it also activates somatosensory receptors of the skin and reduces local pain and muscle spasm. the specific mechanisms of extracorporeal shock wave therapy (eswt) in treating musculoskeletal pain remain unclear. it reduces pain and inflammation by modulating nitrogen-monoxide (no) and vascular endothelial growth factor (vegf). it can destroy sensory unmyelinated nerve fibers, and stimulate neovascularization and collagen synthesis in degenerative tissues.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age with myofascial pain syndrome meeting the simon's diagnostic criteria (5 major and 1 minor) for at least 8 weeks (chronic pain) * no physiotherapy or local injection within 3 months before starting the study exclusion criteria: * acute onset of neck pain * physiotherapy or local injection within 3 months before starting the study * abnormal lab test (esr, hematology) * infection, fever * cervical radiculopathy * uncontrolled hypertension, anticoagulation or defect in blood coagulation * previous cervical operaton

Keywords: extracorporeal shock wave therapy (eswt) low level laser therapy (lllt) myofascial pain syndrome
amyloid prediction in early stage alzheimer's disease through speech phenotyping - past extension

Conditions: Alzheimer Disease; Alzheimer's Disease (Incl Subtypes); Preclinical Alzheimer's Disease; Prodromal Alzheimer's Disease; Mild Cognitive Impairment; Normal Cognition

Summary: the primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage alzheimer's disease, based on archival spoken or written language samples, as measured by the area under the curve (auc) of the receiver operating characteristic curve of the binary classifier distinguishing between amyloid positive and amyloid negative arms. secondary objectives include (1) evaluating how many years before diagnosis of mild cognitive impairment (mci) such algorithms work, as measured on binary classifier performance of the classifiers trained to classify mci vs cognitively normal (cn) arms using archival material from the following time bins before mci diagnosis: 0-5 years, 5-10 years, 10-15 years, 15-20 years, 20-25 years; (2) evaluating at what age such algorithms can detect later amyloid positivity, as measured on binary classifier performance of the classifiers trained to classify amyloid positive vs amyloid negative arms using archival material from the following age bins: younger than 50, 50-55, 55-60, 65-70, 70-75 years old.


Eligibility criteria:
inclusion criteria: * subjects are fully eligible for and have completed the amypred-us (amyloid prediction in early stage alzheimer's disease from acoustic and linguistic patterns of speech) study. (see https://clinicaltrials.gov/ct2/show/nct04928976) * subject has access to audio or written recordings created by them that are available for collection. * subject consents to take part in past extension study. exclusion criteria: * subject hasn't completed the full visit day in the amypred-us study.

Keywords: alzheimer's disease preclinical alzheimer's disease prodromal alzheimer's disease mild cognitive impairment normal cognition amyloid speech acoustic language linguistic machine learning artificial intelligence
pyrophosphate homeostasis and hepatic expression of abcc6.pyro-th

Conditions: Hepatic Failure

Summary: in animals, normal hepatic expression of abcc6 (atp-binding transporter cassette, subfamily c, member 6) determines plasma pyrophosphate (ppi) concentration. ppi prevents the formation of hydroxyapatite crystals on tissues by precipitation of calcium and inorganic phosphate (pi). it is an endogenous compound whose deficiency causes diffuse vascular calcifications in certain rare monogenic diseases, including the elastic pseudoxanthoma caused by the mutation of abcc6. ppi is produced by enzymatic transformation of extracellular atp and, in animals, the liver is the main supplier of atp and ppi (more than 90%). in humans, liver transplantation offers the possibility of correlating the plasma concentration of ppi (\[ppi\]pl) with hepatic expression of abcc6. liver transplantation is performed in the treatment of chronic liver failure (child b or c) or, in the absence of liver failure, in the treatment of hepatocellular carcinoma. by measuring\[ppi\]pl before transplantation and after liver function restoration and by measuring abcc6 in the diseased liver and healthy liver, it is possible to determine whether liver failure is associated with decreased\[ppi\]pl and decreased liver expression of abcc6, which is the objective of our pilot study. its interest is to establish a physiopathological link between the frequent vascular calcifications in obese patients with hepatic steatosis and the production of ppi. prupose: look for a deficit in\[ppi\]pl in patients before the transplant compared to the phase of restoration of liver function


Eligibility criteria:
inclusion criteria: indication for liver transplantation age greater than or equal to 18 years patients affiliated to social security exclusion criteria: patient not affiliated to social security non-consenting patient or unable to understand the protocol and how it works fulminant hepatitis
adjunctive use of celecoxib in the treatment of bipolar postpartum depression

Conditions: Bipolar Disorder; Postpartum Depression

Summary: the investigators will conduct a 6-week, randomized, double-blind, placebo-controlled trial of celecoxib as an add-on treatment to the mood stabilizer among women with bipolar i or ii postpartum depression. women who are taking a mood stabilizer for treatment of bipolar disorder in the postpartum treatment will receive either a placebo or celecoxib add-on treatment. patients will be monitored regularly to assess psychiatric symptoms and side effects. the investigators aim to evaluate the potential antidepressant effect of celecoxib in bipolar postpartum depression.


Eligibility criteria:
inclusion criteria: * women aged 18-45 who are within 3 months of delivering a healthy, term (37 to 40 weeks) singleton * diagnosis of bipolar postpartum depression - depressed with peripartum onset * have a 17-item hamilton rating scale for depression score of \>18 * have failed to respond to an adequate trial of the mood stabilizer * are currently not on any psychotropic drug except a mood stabilizer (lithium, lamotrigine or quetiapine) * are able to communicate (written and oral) in english and capable of giving consent exclusion criteria: * current major depressive episode of more than 6 months duration * a current comorbid psychiatric disorder * history of alcohol or substance abuse within the 12 months before screening * concurrent psychotherapy * high risk for suicide (actively suicidal or a score of = 3 on item #3 on ham-d) * current hepatic, renal, or cardiac disease, chronic pain, coagulation disorders, esophageal or gastro duodenal ulceration within the previous 30 days * known immediate-type hypersensitivity to cox-2 inhibitors, sulfonamides, ibuprofen, or diclofenac * breastfeeding mothers
evaluation of an opioid decrease strategy in chronic

Conditions: Chronic Pain

Summary: increase in the consumption of analgesics observed in many countries with a mediatic crisis resulting in an increasingly frequent wish of patients to wean themselves from opiates. a recent update (b. rolland 2017) suggests that upon initiation of an opioid analgesic treatment, the patient should be informed of the risk of opioid dependence and misuse. there is no clearly validated decay scheme in the event of dependence in patients with chronic non-cancer pain. hypotheses: * possibility of a rapid decrease in opioid analgesic treatments at dcnc sensitized to the risk of dop and mop. (protocol implemented: multidisciplinary assessment, workshops and information sheet on chronic pain, treatments and risk of dop, pharmacological and nonpharmacological adaptation) * highlight the need for additional information from patients and prescribers on the risk of dop and mop in dcnc.

main objective: check if the rapid to semi-rapid regimen (- 25 to -60% dosage in 5 days of hds) of opioid analgesics, without the use of methadone or buprenorphine agonists, in the case of dcnc at the cetd in montpellier is efficient in the medium term (6 months). secondary objective: * with our inclusion questionnaire we wanted to check if the patients had been made aware of the risk of opiate dependence and misuse. * detect the conditions of prescriptions that can promote the misuse of opiates. * evaluating the different components of residual pain at 6 months (type, intensity, anxiety component and depression, function).

Eligibility criteria:
inclusion criteria: * chronic pain patient * major * supported at cetd exclusion criteria: -patient with physical and mental incapacity to participate in the study

Keywords: opioid analgesics opioid use disorders prescription drug abuse treatments prevention identification
jaktinib hydrochloride tablets in the treatment of active ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: this trial uses a multi-center, randomized, double-blind, placebo, parallel-controlled design, and it is expected that about 105 cases will be enrolled in about 10 sites.

the study is divided into two stages, the first stage (1-16 weeks) is the main study; the second stage (17-32 weeks) is the extended study. this study set up 3 groups:jaktinib hydrochloride tablets 75mg bid group, 100mg bid group and a placebo control group. the subjects were randomly enrolled in the group 1:1:1.

Eligibility criteria:
inclusion criteria: * age 18-65, both gender; * active ankylosing spondylitis; * participants who have been treated with non-steroidal anti-inflammatory drugs(nsaids) and still have active disease, or participants who are intolerant to nsaids and stop the drug; * participants receiving low-dose oral glucocorticoid therapy (≤10mg/d prednisone) should maintain a stable medication regimen for at least 4 weeks before the first dose of this study. do not adjust the dose during the entire study period except in emergency situations. * participants receiving other non-prohibited co-drugs should maintain a stable medication regimen for at least 7 days before the first dose of this study; * understand and voluntarily signed informed consent. exclusion criteria: * a history of known or suspected complete spinal rigidity, or clinical and imaging confirmed complete spinal rigidity; * a history of any other autoimmune rheumatic disease; * any history of joint prosthesis infection, and the prosthesis is still in place; * participants who are using strong opioid analgesics (such as methadone, hydromorphone, morphine, etc.); * participants who have been treated with any jak inhibitors (such as tofacitinib, baricitinib, ruxolitinib, filgotinib, upadacitinib, etc.); * participants who have drug abuse or alcohol dependence; * participants who have had herpes virus infection in the past month; * participants who have a history of venous thrombosis (regardless of current treatment); * any significant clinical and laboratory abnormalities that the investigator believes will affect the safety evaluator； * participants who cannot be treated and followed up according to the trial protocol; * any participant considered by the investigator to be unsuitable to participate in this clinical study
radiation exposure of ercp personnel at different standing locations and different patient positions.

Conditions: Occupational Radiation Exposure

Summary: x-ray beam produced during endoscopic retrograde cholangiopancreatography (ercp) affect not only the patient, but the personnel of ercp team may have the effect from the scattered ray. according to the automatic beam adjustment function, the thicker object (eg. lying left lateral) might produce higher scatter ray than thinner object (eg. lying prone). the investigators evaluate the radiation exposure among ercp personnel compare between patient's 2 different positions.

personal solid-state dosimeters were used to measure the radiation dose on personnel during ercp procedure. the real-time effective doses were displayed at a monitoring screen. a dosimeter was attached outside thyroid collar of each ercp team member included of 1st endoscopist, 2nd endoscopist, and nurse anesthetist. patients' age, gender, bmi, body thickness, and indications for ercp were recorded. the patients were randomized into 2 groups by block-of-four. the patients' position was assigned to prone or left lateral decubitus. each ercp personnel wore a lead apron and the dosimeter was attached outside the thyroid collar. the ercp procedure was performed according to the indication in a standard technique. after ercp procedure, the total fluoroscopic time (minute), fluoroscopy tube voltage (kv), fluoroscopy tube current (ma), patient entrance skin dose (mgy) and personnel effective dose (sv) from each dosimeter were recorded. continuous variables were compared by student's t-test or man whitney u-test, where appropriate. categorical variables were compared by chi-square or the fisher exact test. statistical analysis was calculated by using spss statistical software (version17 for window, chicago, usa) and two sided p-value \< 0.05 was considered to be statistical significant.

Eligibility criteria:
inclusion criteria: * indicated for ercp exclusion criteria: * pregnancy * american society of anesthesiologists (asa) physical status class iii - iv * unstable vital signs * patients' position needed to be changed during the procedure * patients who need fixed position for ercp (such as biliary hilar lesion) * enteroscope-assisted ercp * the consent form can not be obtained

Keywords: radiation exposure ercp prone left lateral decubitus
seattle cardiorenal remote ischemic preconditioning trial

Conditions: Congenital Heart Disease; Cardiopulmonary Bypass; Myocardial Injury; Acute Kidney Injury; Acute Lung Injury

Summary: remote ischemic preconditioning (ripc) is a treatment that may be associated with improved outcomes after cardiac surgery. it can be elicited noninvasively by using a tourniquet to elicit transient ischemia over a lower extremity. it is thought to promote anti-inflammatory and cell survival pathways, and thus protect remote organs against future ischemic injury. we hypothesize that compared to sham treatment, ripc will be associated with decreased post-operative acute kidney, myocardial, and lung injury.

in children undergoing cardiac surgery and cardiopulmonary bypass (cpb), our primary aims are to determine whether rpc is associated with: 1) decreased aki and 2) decreased acute myocardial injury. secondary aims include investigating the effects of rpc on post-procedure: 1)acute lung injury and 2) morbidity/mortality.

Eligibility criteria:
inclusion criteria: age birth to 18 years cardiac surgery with planned cardiopulmonary bypass exclusion criteria: any contraindication to compression of lower extremity/extremities body weight \<2 kg active infection going into surgery on renal replacement therapy (rrt) or mechanical circulatory support going into surgery on inotropic support going into surgery

Keywords: pediatric cardiac surgery cardiopulmonary bypass myocardial kidney lung injury
the efficacy and safety study of anti-hypertension combination drug in patients uncontrolled with monotherapy.

Conditions: Hypertension

Summary: the purpose of this study is to evaluate the blood pressure lowering effects of an amlodipine/losartan combination treatment and losartan/hydrochlorothiazide combination treatment in patients with essential hypertension uncontrolled with losartan 100mg monotherapy.

* quality assurance plan was implemented by site monitoring, including data validation and registry procedures and source data verification to assess the accuracy, completeness by comparing the data to external data sources (medical records and paper case report forms). * data dictionary contains the registry, including the source of the variable, coding information (meddra ver12.0), and normal ranges. * statistical analysis were performed using sas® version 9.2, sas institute, cary, nc, usa

Eligibility criteria:
inclusion criteria: * 20 aged or over * patients with blood pressure measured at visit 1; 90mmhg≤msdbp mmhg if on anti-hypertensive drugs, 95mmhg≤msdbp mmhg if not on anti-hypertensive drugs * patients with blood pressure measured at visit 2 were 90mmhg≤msdbp mmhg (non-responder to losartan 100mg for 4-week treatment) exclusion criteria: * patients with too high blood pressure •≥ sitsbp 20mmhg or ≥ sitdbp 10mmhg of variation in three measurements from the reference arm selected at screening * history of hypersensitivity to ccb ,angiotensin ii receptor blockers or sulfonamide. * secondary hypertension or suspected to be
cardiopulmonary exercise testing in cardiosurgery patients

Conditions: Postoperative Complications

Summary: cardiopulmonary exercise testing (cpet) is considered to be a gold standard in pre-operative risk assessment and stratification of high risk patients scheduled for major surgery. surprisingly, only a limited number of studies examined the prognostic role of cpet in cardiothoracic surgery. this is in contrast with rather poor discriminating quality of cardiovascular surgery risk scores and predominantly elderly cardiovascular surgery patients, with significant comorbidity and high degree of frailty. recently, cpet was shown feasible in coronary artery bypass grafting surgery candidates. additionally, the rest parameter, which is the partial pressure of end-tidal carbon dioxide (petco2) and a submaximal exercise parameter (the ve/vco2 slope) with good prognostic utility across multiple respiratory exchange ratio values), has been shown to predict mortality and post-operative complications. whether these rest and submaximal exercise parameters can be used to predict postoperative complications in cardiovascular surgery patients is yet to be determined.


Eligibility criteria:
inclusion criteria: * patients scheduled for coronary artery bypass graft surgery exclusion criteria: * not able to perform cardiopulmonary exercise testing, off-pump revascularization, without full sternotomy, previous cardiac surgery

Keywords: cardiovascular surgery cardiopulmonary exercise testing post-operative complications
the effect of hyperglycaemia on local energy stores in the working muscle in patients with type 1 diabetes mellitus

Conditions: Diabetes Mellitus, Type 1; Exercise

Summary: this study aims at investigating the effect of hyperglycaemia on physical performance and local energy stores in the muscle in patients with type 1 diabetes mellitus under exercise conditions.


Eligibility criteria:
inclusion criteria: * male * aged from 20 to 40 years * patients with type 1 diabetes mellitus lasting for at least 5 years (c-peptide ≤ 0.3 nmol/l in the presence of a plasma glucose level ≥ 7 mmol/l, indicating insulin dependence) * insulin delivery by csii (continuous subcutaneous insulin infusion) for at least 6 months * acceptable to good metabolic control, reflected by an hba1c 5-8% * normal insulin sensitivity, reflected by a daily insulin requirement of 0.3-1.0 u/kg body weight * minimum 30' of moderate exercise 3 times per week * bmi in the range of 18-25 kg/m2 exclusion criteria: * chronic complications of diabetes: * microalbuminuria (mogensen nephropathy stadium ≥ iii) * sensory neuropathy (vibration better than 5/8 at the metatarsophalangeal articulation of digitus i) * proliferating retinopathy * no history of macro-vascular complications * clinically relevant autonomous neuropathy * smoking * abnormal thyroid function * major depression, psychosis and other severe personality disorders, claustrophobia * active neoplasia * contraindications to exposure to a 1.5 t magnetic field (pace-makers, osteosynthetic material, etc.) * abnormal liver or renal function (creatinine \> 130 µmol/l; asat and alat \> 3 times the upper reference limit) * excessive alcohol consumption (\>60g/d) or drug-abuse * refusal to give written informed consent * participation in another study * patients, who are not suitable for the study according to the study physician
multiparametric mri in men with prostate cancer enrolled in active surveillance

Conditions: Prostatic Neoplasms

Summary: to investigate whether multiparametric mri (mp-mri) in patients with low-risk prostate cancer can improve the selection of patients suitable for active surveillance and have a relevance in the ongoing monitoring

men with localized prostate cancer (pca) with small tumor burden may be followed on active surveillance (as) rather than active treatment. as is an attempt to avoid over-treatment of pca, which is estimated to be insignificant at the time of diagnosis, and therefore unlikely to affect patient morbidity and mortality. as include close monitoring with psa measurement (blood test), digital rectal exploration (dre) and trans-rectal ultrasound-guided prostate biopsy (trus-bx) at regular intervals, so that active treatment can be initiated if the cancer becomes more aggressive. it is crucial that patients undergoing as are staged correctly, to avoid underestimating more aggressive disease and patients mistakenly are enrolled into as instead of active treatment. previously, a phd study conducted at herlev hospital revealed that multiparametric mri (mp-mri) of the prostate can improve the detection and staging of pca and may add additional information about tumor aggressiveness compared to the traditional methods dre and trus-bx. mp-mri at the inclusion of as may detect missed significant tumors and potential areas of higher aggressiveness than detected by the traditional biopsies. additional targeted biopsies from these suspicious areas can then be performed with a re-evaluation of the treatment plan, if more advanced disease is identified. conversely, mp-mri has a high negative predicted value for significant disease and can be used to rule out significant pca, reassuring patients and physicians to go on with as. mp-mri has been used at the urology department, herlev hospital, since 2013 in the diagnosis of pca and in the evaluation of patients undergoing as. a retrospective study have show that mp-mri improve the detection of missed significant pca. the main objective of this study is now to prospectively investigate, whether mp-mri can improve the selection of patients suitable for active surveillance and have a relevance in the ongoing monitoring.

Eligibility criteria:
inclusion criteria: * patients with low risk localized prostate cancer enrolled in active surveillance exclusion criteria: * metastatic prostate cancer * no mp-mri data present * prostate cancer treatment * known allergic reaction to gadolinium-based mri contrast agent * prostate biopsy during the last 21 days * impaired renal function with gfr \< 30 ml / min * pacemaker * magnetic metal residues in the body * claustrophobia * psychiatric disorders * age under 18 year

Keywords: prostate biopsy prostate cancer magnetic resonance imaging neoplasm staging